Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) Q4 2015 Earnings Conference Call - Final Transcript
Feb 23, 2016 • 04:30 pm ET
Good day, and welcome to the Jazz Pharmaceuticals plc Full Year and Fourth Quarter 2015 Earnings Conference Call. Following an introduction from the Company, we will open the call to questions. As a reminder, this call is being recorded.
I will now turn the call over to Kathee Littrell, Head of Investor Relations at Jazz Pharmaceuticals.
Thank you, Cath, and thank you for joining our Investor Call. Today, we reported our fourth quarter and full year financial results and 2015 financial guidance in a press release. The release and the slide presentation accompanying this call are available on the Investors section of our website.
With me for today's call are Bruce Cozadd, Chairman of the Board and CEO; Matt Young, our Chief Financial Officer; Russ Cox, our Chief Operating Officer; Mike Miller, our Head of U.S. Commercial; and Karen Smith, Global Head of R&D and Chief Medical Officer. Following some remarks, we'll open the call for your questions.
I'd like to remind you that some of the statements we will make on this call relate to future events and future performance rather than historical facts and are forward-looking statements. Examples of forward-looking statements include statements related to our 2016 financial guidance and goals; future product sales and volume due to regulatory, litigation and intellectual property-related events; clinical trials and other product development activities; our commercial goals and initiatives, including the potential approval of our NDA for defibrotide and commercial launch of defibrotide in the U.S.; our corporate development efforts and the timing of such events and activities.
These forward-looking statements involve numerous risks and uncertainties that could cause actual events, performance and results to differ materially. These risks and uncertainties are identified and described in today's press release, the slide presentation accompanying this call and under Risk Factors in our Form 10-Q for the quarter ended September 30, 2015, and our Form 10-K for the year ended December 31, 2015, that we expect to file shortly. We undertake no duty or obligation to update any forward-looking statements we make today.
On this call, we will discuss several non-GAAP financial measures, including historical and expected 2016 adjusted net income attributable to Jazz Pharmaceuticals and the related per-share measures and historical and expected 2016 adjusted SG&A and R&D expenses. We believe that these non-GAAP financial measures are helpful in understanding our past financial performance and potential future results.
They are not meant to be considered in isolation or as a substitute for comparable reported GAAP measures. Reconciliations of GAAP to non-GAAP financial measures discussed on this call are included in today's press release and the slide presentation accompanying this call. Both are posted in the Investors section of our website.
I'll now turn the call over to Bruce.
Good afternoon, everyone, and thank you for joining us. Our solid progress as a company in 2015 has positioned us well for 2016 and beyond. In 2015, we grew both our top and bottom line, consistent with guidance, and also made important progress on a